文献速递脑血管病

前循环串联闭塞的血管内治疗:TITAN与ETIS登记汇总分析

Endovascular Therapy of Anterior Circulation Tandem Occlusions: Pooled Analysis From the TITAN and ETIS Registries.
PubMed 文献 · Stroke · 2021-08-10

本研究汇总法国ETIS和国际TITAN两个前瞻性多中心登记中前循环串联闭塞接受血管内治疗的患者数据,比较急性颈内动脉病变支架置入与非支架治疗的功能与安全结局。倾向评分加权分析显示支架组90天良好结局和成功再灌注的odds更高,但任何脑出血的odds也更高,症状性出血未增加;亚组分析提示获益仅见于动脉粥样硬化病变患者。

要点

  • 急性颈内动脉支架置入与更高的90天良好结局和成功再灌注相关。
  • 支架组任何脑出血风险更高,但症状性出血和实质出血2型未增加。
  • 获益仅见于动脉粥样硬化病变患者,病变类型间存在异质性。

核心结论

  • 急性颈内动脉支架置入治疗串联闭塞患者90天良好结局的odds更高,但任何脑出血的odds也更高,且多数脑出血为无症状性。

研究设计与样本

  • 汇总法国前瞻性多中心观察性ETIS登记(2013年1月至2019年7月)和国际TITAN登记(2012年1月至2016年9月)的个体患者数据。
  • 纳入因前循环串联闭塞接受血管内治疗的急性缺血性卒中患者,按颈内动脉病变治疗分为支架组和非支架组,使用倾向评分方法比较结局。

主要发现

  • 共纳入603例患者,其中341例接受急性颈内动脉支架置入。
  • 未调整分析中,支架组90天mRS 0–2比例为57% vs 45%,90天mRS 0–1比例为40% vs 27%。
  • 倾向评分加权调整后,支架组良好结局的adjusted odds ratio为1.09(95% CI 1.01–1.19;P=0.036)。
  • 支架组成功再灌注(mTICI 2b-3)的adjusted odds ratio为1.19(95% CI 1.11–1.27;P<0.001)。
  • 支架组任何脑出血的adjusted odds ratio为1.10(95% CI 1.02–1.19;P=0.017),症状性颅内出血或实质出血2型未增加。

关键数值与推荐

  • 亚组分析显示病变类型(动脉粥样硬化 vs 夹层)间存在异质性,P for heterogeneity=0.01。
  • 急性颈动脉支架置入的获益仅见于动脉粥样硬化病变患者。

临床怎么用

  • 对于前循环串联闭塞的急性缺血性卒中患者,急性颈内动脉支架置入可能改善90天功能结局和成功再灌注。
  • 支架置入增加任何脑出血风险,但多数为无症状性,需结合病变类型(动脉粥样硬化 vs 夹层)个体化决策。

局限性

  • 本研究为汇总登记数据的观察性分析,非随机对照试验。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Endovascular therapy for tandem occlusion strokes of the anterior circulation is an effective and safe treatment. The best treatment approach for the cervical internal carotid artery (ICA) lesion is still unknown. In this study, we aimed to compare the functional and safety outcomes between different treatment approaches for the cervical ICA lesion during endovascular therapy for acute ischemic strokes due to tandem occlusion in current clinical practice. METHODS: Individual patients’ data were pooled from the French prospective multicenter observational ETIS (Endovascular Treatment in Ischemic Stroke) and the international TITAN (Thrombectomy in Tandem Lesions) registries. TITAN enrolled patients from January 2012 to September 2016, and ETIS from January 2013 to July 2019. Patients with acute ischemic stroke due to anterior circulation tandem occlusion who were treated with endovascular therapy were included. Patients were divided based on the cervical ICA lesion treatment into stent and no-stent groups. Outcomes were compared between the two treatment groups using propensity score methods. RESULTS: A total of 603 patients were included, of whom 341 were treated with acute cervical ICA stenting. In unadjusted analysis, the stent group had higher rate of favorable outcome (90-day modified Rankin Scale score, 0–2; 57% versus 45%) and excellent outcome (90-day modified Rankin Scale score, 0–1; 40% versus 27%) compared with the no-stent group. In inverse probability of treatment weighting propensity score–adjusted analyses, stent group had higher odds of favorable outcome (adjusted odds ratio, 1.09 [95% CI, 1.01–1.19]; P=0.036) and successful reperfusion (modified Thrombolysis in Cerebral Ischemia score, 2b-3; adjusted odds ratio, 1.19 [95% CI, 1.11–1.27]; P<0.001). However, stent group had higher odds of any intracerebral hemorrhage (adjusted odds ratio, 1.10 [95%, 1.02–1.19]; P=0.017) but not higher rate of symptomatic intracerebral hemorrhage or parenchymal hemorrhage type 2. Subgroup analysis demonstrated heterogeneity according to the lesion type (atherosclerosis versus dissection; P for heterogeneity, 0.01), and the benefit from acute carotid stenting was only observed for patients with atherosclerosis. CONCLUSIONS: Patients treated with acute cervical ICA stenting for tandem occlusion strokes had higher odds of 90-day favorable outcome, despite higher odds of intracerebral hemorrhage; however, most of the intracerebral hemorrhages were asymptomatic.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Anadani M, Marnat G, Consoli A, et al. Endovascular Therapy of Anterior Circulation Tandem Occlusions: Pooled Analysis From the TITAN and ETIS Registries. Stroke. 2021. PMID: 34372671. doi:10.1161/STROKEAHA.120.033032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。